Early Detection of Broken Hearts in Cancer Patients: Bevacizumab, Sunitinib and Heart Failure

Trial Profile

Early Detection of Broken Hearts in Cancer Patients: Bevacizumab, Sunitinib and Heart Failure

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib (Primary)
  • Indications Colorectal cancer; Gastrointestinal stromal tumours; Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms ASPER
  • Most Recent Events

    • 28 Jan 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 08 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
    • 08 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top